BCAX (Bicara Therapeutics) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Days Payable?

Bicara Therapeutics's average Accounts Payable for the three months ended in Sep. 2024 was $3.32 Mil. Bicara Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Bicara Therapeutics's Days Payable or its related term are showing as below:

BCAX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.79
* Ranked among companies with meaningful Days Payable only.

Bicara Therapeutics's Days Payable stayed the same from Jun. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Bicara Therapeutics Days Payable Historical Data

The historical data trend for Bicara Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Days Payable Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Days Payable

Bicara Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's Days Payable

For the Biotechnology subindustry, Bicara Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Bicara Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (5.137	+	3.186)	/	2 )	/	0	*	365
=	4.1615					/	0	*	365
=	N/A

Bicara Therapeutics's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (4.683	+	1.962)	/	2 )	/	0	*	365 / 4
=	3.3225					/	0	*	365 / 4
=	N/A

Bicara Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.